Heart failure is one of the leading causes of death worldwide and has been singled out as an emerging epidemic. With a 5-year survival rate of 50%, heart failure poses a tremendous burden on our economic and healthcare system. Despite extensive interests and paramount clinical needs, our understanding of heart failure remains incomplete. As a consequence, there is currently no cure.

Hypertension is one of the most important risk factors of heart failure. Under high blood pressure, cardiac ventricular wall stress is mounted. According to Laplace’s law, an increase in cardiac wall thickness can effectively ameliorate wall stress. This so-called concentric cardiac growth is achieved by upregulation of sarcomere biosynthesis and enlargement of individual cardiac myocytes attributed to limited replicative capacity in the adult heart. In response to persistent stress, however, this once adaptive hypertrophic growth may progress into decompensation and heart failure. Over the past few decades, numerous signaling molecules and pathways have been identified in cardiac hypertrophic growth and heart failure. These processes involve extensive cardiac remodeling in metabolism, structure, and electrophysiology. Growing evidence indicates that metabolic remodeling precedes most, if not all, other pathological alterations and likely plays an essential role in cardiac hypertrophy and heart failure. Ischemic heart disease is another critical contributing factor to heart failure. Patients surviving myocardial infarction (MI) may undergo extensive pathological remodeling in the heart with major metabolic derangements. Here, we review recent findings of cardiac metabolic changes in response to hemodynamic stress and cardiac ischemia with a focus on glucose utilization. We also discuss potential therapeutic targets from carbohydrate metabolic pathways to tackle this devastating heart disease.

Glucose Metabolism in the Heart

The heart is an omnivore, consuming fuel constantly and using any substrate available. The high rates of ATP production and turnover are critical in maintaining cardiac contractility to deliver blood and oxygen to the other organs. Under normal conditions, cardiac ATP is mainly derived from fatty acid (FA) oxidation (FAO), with glucose metabolism contributing less. However, under stress conditions, FAO may be reduced, which is concomitant with increased glucose utilization. Glucose uptake in cardiomyocytes is mediated by glucose transporters (GLUTs), with GLUT1 and GLUT4 as the most abundant isoforms. Whereas GLUT1 is highly expressed in the fetal heart, GLUT4 is predominant in the adult heart. Inside cardiac myocytes, glucose may be first phosphorylated to glucose 6-phosphate by hexokinase or converted to sorbitol by the polyol pathway. Glucose 6-phosphate subsequently goes through multiple metabolic pathways, including glycolysis, pentose phosphate pathway (PPP), and the hexosamine biosynthetic pathway (HBP; Figure 1). Pathological alterations of these pathways in cardiac hypertrophy and ischemic heart disease are associated with impaired signaling transduction, perturbed ion and redox homeostasis, and contractile dysfunction.

Glycolysis

Glycolysis is arguably the most important route for glucose metabolism in a cell, which produces pyruvate, NADH, and ATP. ATP yield from glycolysis, however, contributes only a small portion of the overall ATP pool in the normal heart. In cytosol, pyruvate can be further utilized to form alanine by alanine transaminase or reduced to lactate by lactate dehydrogenase. On the other hand, pyruvate is oxidized (known as pyruvate oxidation or glucose oxidation) to generate acetyl-CoA by pyruvate dehydrogenase that fuels the tricarboxylic acid cycle in mitochondria. Three enzymes,
including hexokinase, phosphofructokinase (PFK), and pyruvate kinase, catalyze irreversible reactions of glycolysis; thus, they are proposed as critical enzymes in governing glycolysis.\textsuperscript{18} The control of glycolysis is variably distributed between enzymes and counts on the substrate, hormone, oxygen deficiency, or other different conditions.\textsuperscript{19} Hexokinase is the first enzyme of glycolysis. Its control of glucose transport is abrogated in the presence of insulin whereas its usage of glucose is favored in the presence of ketones. The second regulatory enzyme of glycolysis is PFK that has 2 isoforms: PFK1 and PFK2. Fructose 6-phosphate is converted to fructose 1,6-bisphosphate and fructose 2,6-bisphosphate (fructose 2,6-BP) by PFK1 and PFK2, respectively (Figure 2). Fructose 2,6-BP is a potent activator of PFK1 for production of fructose 1,6-bisphosphate and following glycolytic flux.\textsuperscript{20} Pyruvate kinase, the final enzyme of glycolysis, regulates the flux from this pathway. Its control of glycolysis is increased during cardiac perfusion with glucose in the presence of ketones or insulin or both.\textsuperscript{19} Studies have shown that glycolysis plays a crucial role in maintaining contractile function attributed to the tight coupling of glycolysis-derived ATP with ion pump ATPase.\textsuperscript{21}

**Glycolysis in the Hypertrophic Heart**

During cardiac hypertrophic growth and pathological remodeling, there is a prominent metabolic shift from FAO to glucose utilization. This alteration is associated with an increase in glycolysis in hypertrophied hearts (Table).\textsuperscript{22–25} At the mechanistic level, intracellular free AMP in the cardiomyocyte is increased when the heart faces pressure overload, which consequently transduces signaling through AMP-
### Table. Phenotypes of the Animal Models in Which Glucose Metabolism Is Altered

| Animal Model                                      | Background | Condition                  | Events                                                                 | Cardiac Outcome                      | References |
|--------------------------------------------------|------------|----------------------------|------------------------------------------------------------------------|---------------------------------------|------------|
| Cardiac-specific knockout of GLUT4               | C57BL/6, FVB | Baseline                  | ↑Insulin-independent glucose uptake                                   | Mild hypertrophy                      | 12         |
|                                                  |            |                            | ↓Insulin-dependent glucose uptake                                      |                                       |            |
|                                                  |            | I/R                       | ↑Glycolysis                                                            |                                       |            |
|                                                  |            |                           | ↑Glucose-independent glucose uptake                                    |                                       |            |
| Cardiac-specific overexpression of GLUT1         | FVB        | Baseline                  | ↑Insulin-independent glucose uptake                                   | Normal                                | 14         |
|                                                  |            |                            | ↑Glycolysis                                                            |                                       |            |
|                                                  |            | 8 wks post-TAC             | ↔Myocardial energetics                                                 |                                       |            |
| Inducible cardiac-specific overexpression of GLUT1 | FVB        | Baseline (6–10 wks old)   | ↑Glucose utilization, glycolysis                                       | Normal                                | 15         |
|                                                  |            |                            | ↑Glycolysis                                                            |                                       |            |
|                                                  |            | 4 wks post-TAC             | ↓Glycolysis                                                            |                                       |            |
| Cardiac-specific knockout of GLUT1               | C57BL/6    | Baseline (6–10 wks)       | ↓Glycolysis, glucose oxidation                                         | Normal                                | 16         |
|                                                  |            |                            | ↑FAO                                                                  |                                       |            |
|                                                  |            | 4 wks post-TAC             | ↓Glycolysis, glucose oxidation                                         | ↔Hyperthrophy                         |            |
|                                                  |            |                            | ↑FAO                                                                  | ↔Mitochondrial function               |            |
| Cardiac-specific kinase-deficient PFK-2          | FVB        | Baseline (3–4 m)          | ↓Glycolysis, [F-2,6-P2], [F-1,6-P2], [G-6-P], [F-6-P], [UDP-GlcNAc], [glycogen] | Mild hypertrophy, ↑Fibrosis          | 24         |
|                                                  |            |                            | ↑Glucose sensitivity                                                  | ↑Cardiac function                     |            |
|                                                  |            | 13 wks post-TAC            | ↓[F-2,6-P2], glycolysis                                               | ↑Cardiac hypertrophy, ↑Fibrosis, cardiac dysfunction | 25         |
| WT                                               | FVB/NJ     | 4 wks of treadmill training| ↓Glycolysis, PFK activity, acute                                     | ↑Physiological hypertrophy            | 30         |
|                                                  |            |                            | ↓Glycolysis, PFK activity, recovered                                    | ↑Cardiac function                     |            |
| Cardiac-specific kinase-deficient PFK-2          |            | Baseline (15–16 wks old)  | ↓Glycolysis, PFK activity                                             | ↑Physiological hypertrophy            |            |
| Cardiac-specific phosphatase-deficient PFK-2     |            | Baseline (15–16 wks old)  | ↑Glycolysis                                                            | ↑Pathological hypertrophy             |            |
| Cardiac-specific phosphatase-deficient PFK-2     | FVB/NJ     | Baseline (3–4 m)          | ↑Glycolysis, [F-2,6-P2]                                               | ↑Cardiac hypertrophy, fibrosis, ↑Hypoxia-induced contractile inhibition in cardiomyocytes | 31         |
|                                                  |            |                            | ↑[G-6-P], [glycogen], FAO                                              |                                       |            |
|                                                  |            | I/R                       | ↔Insulin sensitivity                                                  | ↔Myocardial infarct size              |            |
| AR-null mice                                      | C57BL/6    | Base line (14–16 wks old) | ↑Lipid peroxidation-derived aldehydes                                 | Ejection fraction, slightly           | 63         |
|                                                  |            |                            | ↑Aldehyde-modified proteins                                           |                                       |            |
|                                                  |            | 2 wks post-TAC (12–16 wks old) | ↑Lipid peroxidation-derived aldehydes                                 | ↑Pathological cardiac hypertrophy    |            |
|                                                  |            |                            | ↑Aldehyde-modified proteins                                           | ↑Cardiac function                     |            |
| Cardiac-specific overexpression of human AR      | C57BL/6    | Baseline (3 m)            | ↓Glucose uptake                                                        | Normal                                | 79         |
|                                                  |            |                            | ↓GLUT1, GLUT4, CPT1, AOX mRNA                                          |                                       |            |
|                                                  |            |                            | ↑SDH mRNA level                                                        |                                       |            |
|                                                  |            | Baseline (12 m)           | ↑FA metabolism                                                        |                                       |            |
|                                                  |            | I/R                       | ↓mRNA levels of FA metabolism related genes                           | ↑Cardiac dysfunction, ↑Infarct size, apoptosis |            |
|                                                  |            |                            | ↑ROS                                                                  |                                       |            |
|                                                  |            |                            | ↑FAO, PDK4                                                             |                                       |            |
|                                                  |            |                            | ↑Glucose uptake/utilization                                          | ↑Apoptosis, fibrosis, ↑Cardiac function |            |

Continued
activated protein kinase. As a result, synthesis of fructose 2,6-BP, an activator of PFK1, is upregulated and glucose transporter migration to sarcolemmal membrane is enhanced. Consistently, a transgenic mouse model overexpressing kinase-deficient PFK2 in cardiomyocytes has reduced glycolysis attributed to the low level of fructose 2,6-BP. These mice exhibit more-profound hypertrophy, elevated fibrosis, and cardiac dysfunction than control animals in response to pressure overload. Failure to increase fructose 2,6-BP and glycolysis may therefore contribute to the deleterious structural and functional changes in the heart. Taken together, elevation of glycolysis through activation of fructose 2,6-BP and PFK1 is an adaptive response to cardiac pressure overload. The increase in glycolysis is, however, accompanied by reduced or normal glucose oxidation, which may lead to an uncoupling between glucose uptake and oxidation. This imbalance has been implicated in pathological hypertrophic remodeling in the heart.

| Animal Model | Background | Condition | Events | Cardiac Outcome | References |
|--------------|------------|-----------|--------|-----------------|------------|
| G6PD-deficient | C3H/HeJ | 3 m | *Oxidative stress ↓[Ca²⁺], transport | Normal | 99 |
| | | 9 m | ↓Superoxide production | ↓Cardiac function over time | |
| | | 6 wks post-TAC | ↓Aconitase | Tendency to develop LV dilation | 100 |
| | | 17 wks post-TAC (high fructose diet) | ↓Oxidative stress | ↑Pathological hypertrophy, ↓Cardiac function |  |
| | | 3 m post-MI | ↑Glycolysis, ↓[Ca²⁺], ↓Serine kinase | ↑LV dilation ↔Cardiac function, survival |  |
| | | 17 wks post-TAC (high fructose diet) | ↓Glycolysis | |  |
| | | I/R | ↓Cellular glutathione (GST, GSH) | | 108 |
| | | | | |  |
| Cardiac-specific overexpression of HK2 | FVB/N | Baseline (2–3 mo old) | ↑O-GlcNAcylation | ↑Cardiac hypertrophy | 101 |
| | | | | |  |
| Cardiac-specific knockout of OGT | C57BL/6 | Baseline (4–5 wks) | ↑COX IV, HK, PFK, GLUT1 mRNA levels | Perinatal death and heart failure, ↑Apoptosis, fibrosis, ER stress, ↑Cardiac hypertrophy | 133 |
| | | | | |  |
| Cardiac-specific het of OGT | C57BL/6 | Baseline (2–4 m) | | Progressive cardiomyopathy |  |
| | | | | |  |
| Inducible cardiac-specific knockout of OGT | C57BL/6 | Baseline (<1 m) | ↑GAPDH mRNA level | ↑Cardiac hypertrophy | 133,158 |
| | | Baseline (1–3 m) | | | 133 |
| | | 2 and 4 wks post-TAC | ↑TGFβ2 mRNA level, ↓GATA4 | ↑Cardiac function | 134 |
| | | 5 d post-MI | ↑PGC1-α, PGC1-β, CPT1, CPT2, MCAD, ATP-50, COXIV-5B, GLUT1, GLUT4 mRNA levels | | 158 |
| | | 4 wks post-MI | | ↑Apoptosis, fibrosis, ↓Cardiac function | |
| | | | | |  |
| Ventricular-specific knockout of HIF1α | C57BL/6 | Baseline | ↑GLUT1, HK2, GPD1, GPAT, PPARγ mRNA levels, ↓PPARα, PPARβ/δ mRNA levels, ↑Mitochondrial-related genes at mRNA levels, ↑PGC1α, M-CPT1, VDAC, SDHA, ↑Respiratory function, DNA content, surface area of mitochondria, ↑SERCA2, Ca²⁺ reuptake, ↑ATP, phosphocreatine, lactate | ↑Contractile function, mild hypovascularity | 166,167 |
| | | 14 to 18 d post-TAC | ↑TAG content, ↑GAPDH, GPD1, GPAT activities | | 166 |

Continued
Metabolic alterations in the heart for glycolysis, glucose oxidation, and FAO may vary depending on the animal models, experimental settings, stage and severity of cardiac hypertrophy and dysfunction, and different pathological stimuli. Although evidence is mounting to support decreased FAO and increased glucose utilization, unchanged or elevated FAO and unchanged or decreased glycolysis have also been found in hypertrophied hearts. Angiotensin II induces cardiac hypertrophy and dysfunction, along with preservation of FAO and glycolysis (slightly reduced, but not significant) and decreases in glucose and lactate oxidation. Here, glycolysis rate may be modulated by the sustained/high FAO rate through PFK1 inhibition and development of cardiac insulin resistance. Angiotensin II has been found to induce insulin resistance, which may lead to impairment of insulin-dependent glucose uptake and glycolysis. Consistently, the defect in insulin-induced GLUT4 translocation may cause reduction of glycolysis in abdominal aortic constriction hearts. Under insulin resistance, metabolic flexibility of utilizing FAs and glucose is impaired. Therefore, the uncoordinated regulation of glucose oxidation, glycolysis, and FAO may result in ATP deficit and development of heart failure.

Under physiological context, exercise may acutely suppress glycolysis and PFK activity, which are then augmented in the recovery stage. It is implied that changes in glucose utilization caused by regular exercise are important for maintaining mitochondrial health and physiological cardiac growth, whereas a consistently high rate of glycolysis induces pathological hypertrophy.

Glycolysis in the Ischemic and Failing Heart

Consequences of cardiac ischemia include poor oxygen supply and inadequate washout of metabolic wastes. Lack of sufficient oxygen dampens cardiomyocyte capacity to break down FAs, which, in turn, decreases the level of cellular citrate and indirectly activates glucose uptake and glycolysis. As a result, glycolytic flux increases during ischemia. It has been shown that glucose uptake increases in mild ischemia, whereas it may actually decrease in severe ischemia (near-complete blockage of coronary flow). When the coronary flow rate progressively reduces, modest ischemia will become moderate and then severe. During this transition, glycolysis produces ATP and maintains ionic homeostasis, providing a beneficial effect. However, under severe ischemia, glycolysis may be more harmful than beneficial. Lack of washout can lead to deleterious effects overshadowing the benefit of generation of anaerobic ATP. Buildup of intracellular protons attributed to poor perfusion may inhibit glycolysis in a feedback manner. Further detrimental effects may include disruption of ionic homeostasis by debilitating the Na+\(^+\)/K+ efflux capacity of Na+/K+ ATPase and Ca\(^{2+}\) ATPase, thereby impairing contractile function. In addition, pyruvate from glycolysis forms lactate rather than entering pyruvate oxidation, which may lead to an even higher level of lactate and lower rate of glucose oxidation. Collectively, in a manner similar to that proposed in pathological cardiac hypertrophy, increased glycolysis may be accompanied by uncoupling of glucose oxidation and elevation of lactate and proton levels, which, together, contribute to myocardial injury.

Restoration after ischemia (ischemia/reperfusion; I/R) is the most effective approach to mitigate cardiac damage and improve clinical outcomes. However, during reperfusion, the glycolytic rate is still high without a parallel increase in glucose oxidation, resulting in continuous reduction in cardiac efficiency. Moreover, I/R restores extracellular pH and induces Na\(^+/\)H\(^-\) and Na\(^+\)/Ca\(^{2+}\) exchange, which may
adversely cause profound intracellular overload of Na\(^+\) and Ca\(^{2+}\). Therefore, ionic imbalance is persistent during reperfusion that is considered a culprit for impaired contractility.\(^{46}\) During reperfusion, the increase in FAO is accompanied by a decrease in glucose oxidation, which causes further uncoupling between glucose oxidation and glycolysis.\(^{50,51}\)

In congestive heart failure, the rate of FA utilization is induced whereas the glucose utilization rate is suppressed.\(^{52,53}\) The high level of plasma norepinephrine may account for the elevated plasma free FAs through lipolysis and re-esterification, which, in turn, causes the decrement in glucose oxidation.\(^{54}\) Suppression of FAO may represent a promising strategy to improve myocardial energy homeostasis.

In line with aforementioned animal studies, the uncoupling between glycolysis and glucose oxidation has also been discovered in human failing hearts.\(^{55,56}\) Furthermore, high-salt-diet–induced heart failure with preserved ejection fraction shows a progressive increase in glycolysis along with the development of hypertrophy and diastolic dysfunction without changes in glucose oxidation. The mismatch between glycolysis and glucose oxidation in the early stage may cause the development of heart failure with preserved ejection fraction.\(^{56}\) Restoration of the coupling may be a potential therapeutic means for treatment of heart failure.\(^{44–46,56}\)

It is worth noting that the reduction of FAO is not observed in onset of heart failure with preserved ejection fraction, but only at the later stage.\(^{56}\) In support of this, the rate of FA utilization, including FAO and lipid incorporation, is inversely correlated with degree of cardiac dysfunction in chronically infarcted rat hearts.\(^{57}\) FAO and glucose oxidation are unaltered in dogs with moderate coronary microembolization-induced heart failure.\(^{58}\) Furthermore, substrate utilization (eg, FAO) in patients with moderate heart failure is similar to healthy controls.\(^{59}\) These data suggest a significant contribution of the reduced FA utilization to the late stage of heart failure. The difference in metabolic remodeling is likely determined by the type and severity of cardiac disease. Further studies are warranted to dissect the underlying mechanisms for future clinical applications.

### Polyol Pathway

The polyol pathway consists of 2 enzymatic steps (Figure 3). The first reaction is controlled by aldose reductase (AR) for reduction of glucose to sorbitol. The second involves the action of sorbitol dehydrogenase to oxidize sorbitol to fructose. Under euglycemic conditions, <3% of glucose is utilized by the polyol pathway, whereas >30% of glucose is metabolized through this process in the intact rabbit lens under hyperglycemia.\(^{60,61}\) In the heart, however, the metabolic rate through the polyol pathway remains undefined. AR and sorbitol are known to maintain osmotic balance by regulating the volume and intracellular environment of renal cells in response to alterations of external osmolality.\(^{62}\) Under hyperosmotic conditions, AR is induced in rat kidney mesangial cells, Chinese hamster ovary cells,\(^{63}\) JS1 Schwann cells,\(^{64}\) and rat cardiomyocytes.\(^{65}\) Additionally, overwhelming evidence suggests that AR may act as an antioxidant enzyme.\(^{66,67}\) Under high oxidative stress conditions, such as vascular inflammation,\(^{68,69}\) ischemia,\(^{70}\) iron overload,\(^{71}\) and alcoholic liver disease,\(^{72}\) AR is elevated. At the functional level, induction of AR displays cytoprotection against oxidative stress in the Chinese hamster fibroblast cell line.\(^{73}\) Moreover, AR may regulate other glucose metabolic pathways such as glycolysis and glucose oxidation.

#### Polyol Pathway in the Hypertrophic Heart

Limited studies have been directed to dissect the role of polyol pathway in development of pathological cardiac hypertrophy. Recently, it has been reported that cardiac AR expression\(^{28}\) and its products (fructose and sorbitol)\(^{74}\) are induced in hypertrophied hearts and loss of AR leads to more-profound hypertrophic growth and cardiac dysfunction.\(^{28}\) AR has been shown to hold the activity of detoxification of reactive aldehydes generated by lipid peroxidation. AR deficiency in hypertrophied hearts may therefore impair reactive aldehydes removal, resulting in elevation of aldehyde-modified proteins such as 4-hydroxynonenal (HNE)-protein and acrolein-protein adducts. These modified proteins participate in ATP production, protein folding, and autophagy.\(^{28}\) Autophagy in the early stage of hypertrophic growth is

---

**Figure 3.** The polyol pathway in the heart. In the polyol pathway, aldose reductase (AR) converts glucose to sorbitol, which is subsequently oxidized to fructose by sorbitol dehydrogenase (SDH). AR also acts as an antioxidant enzyme by catalyzing toxic aldehyde to nontoxic alcohol. AGES indicates advanced glycation end products; fructose 6-P, fructose 6-phosphate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GLUT, glucose transporter; GR, glutathione reductase; GSH, reduced glutathione; GSSG, oxidized glutathione; ROS, reactive oxygen species.
adaptive; however, excessive autophagy may induce mal-adaptive cardiac remodeling. Acute increase of AR in cardiac hypertrophy may therefore serve as an adaptive defensive response to detoxify aldehydes and govern autophagy. However, further studies are required for better understanding of the mechanistic insights by which the polyol pathway regulates cardiac pathological remodeling.

**Polyol Pathway in the Ischemic and Failing Heart**

AR functions as an antioxidant enzyme in protecting hearts and arteries from the toxic effects of lipid peroxidation products such as HNE and reactive aldehydes. Specifically, the generation of nitric oxide and activation of protein kinase C are required for the action of AR in the late phase of ischemic preconditioning, which consequently diminishes the injury caused by lipid peroxidation products. Reduction of AR expression and activity in dogs’ failing hearts results in abnormal lipid-peroxidation–derived aldehyde metabolism and contributes to the excessive buildup of reactive aldehydes, which may amplify chronic oxidative stress.

Although ample findings support a beneficial effect of the polyol pathway during ischemia, some studies have shown its contribution to the vulnerability of cardiovascular complications in diabetes mellitus, ischemia, and aging. AR activation has been observed in ischemic hearts, which may exacerbate cardiac damage after I/R and cause cardiac dysfunction in aging mice. Here, AR may drive the conversion of glucose to fructose and diminish FA utilization. Additionally, AR may exacerbate I/R injury by impairment of mitochondrial membrane function through inducing oxidative stress (ie increase in malondialdehyde contents and decrease in mitochondrial antioxidant manganese superoxide dismutase activity).

Moreover, inhibition of AR shows cardioprotection in diabetic and ischemic mice. The anti-ischemic effects likely involve improving cardiac energy metabolism and contractile function, suppressing oxidative stress, and preserving mitochondrial function. Indeed, polyol pathway inhibition is linked to a higher rate of glycolysis and more-prominent ATP generation. Elevated glycolysis and reduction of oxidative stress by AR inhibition have been proposed to cause the reduction of NADH/NAD+ by attenuation of NAD+ use through sorbitol dehydrogenase; hence, NAD+ is preserved for glyceraldehyde 3-phosphate dehydrogenase in glycolysis. Additional evidence for the antioxidant effect of AR inhibition is that it may reserve NADPH to fuel the glutathione reductase pathway. Inhibition of AR attenuates I/R injury along with the decrease in reactive oxygen species (ROS), malondialdehyde, and thiobarbituric acid reactive substances, the by-product of lipid peroxidation. Furthermore, AR inhibitor may attenuate elevation of Na+ and Ca2+ during I/R. This effect has been explained, in part, by induction of sodium and calcium efflux resulting from activation of Na+/K+ ATPase and Na+/Ca2+ exchanger by the AR inhibitor. Additionally, inhibition of AR restores the activity of Ca2+ ATPase by dampening tyrosine nitration and normalizing S-glutathionylation of this pump. Ectopic lipid accumulation in the heart may contribute to the pathogenesis of cardiovascular disease. AR promotes lipid accumulation in the heart by competing with histone deacetylase 3 for histone deacetylase 3 for degrada-

The role of the polyol pathway on redox stress in diabetes mellitus is emerging. A reduced content of NADPH has been found in diabetic lung and pancreas. The usage of NADPH by AR may reduce NADPH availability for glutathione reductase to maintain reduced glutathione and may induce superoxide generation. Moreover, NADH level is elevated in chronic hyperglycemia that involves reduced glycosylation, impairment of mitochondrial function, and augmented ROS generation. This increase of NADH may be associated with the polyol pathway. The usage of NAD+ by sorbitol dehydrogenase, the second step in the polyol pathway, can reduce the content of NAD+ for glycolysis and produce NADH. In addition, fructose produced by the polyol pathway is converted into fructose 3-phosphate and leads to generation of 3-deoxyglu-

It is worth mentioning that the osmotic consequence of activated polyol pathway in diabetes mellitus is one of the potential pathological mechanisms. Accumulation of sorbitol causes hyperosmotic stress, which is associated with development of diabetic cataract, reduced Na+/K+ ATPase activity, elevated oxidative stress, and ATP deficit. In cultured rat cardiomyocytes, AR not only contributes to the depletion of glutathione content, but also hyperosmotic stress-induced apoptosis. Taken together, it is possible that the role of the polyol pathway or AR in the heart depends on the context of pathological cardiac disease. More work remains to be done to understand how the polyol pathway senses the signals to defend or exacerbate cardiac injury under different pathological contexts.

**Pentose Phosphate Pathway**

There are 2 branches in the PPP: oxidative and nonoxidative. The oxidative PPP generates NADPH and ribulose 5-phosphate (Figure 4). On the other hand, the nonoxidative branch
metabolizes ribulose 5-phosphate to 5-carbon sugars for nucleotide biosynthesis or generation of intermediates for the glycolytic pathway (ie, glyceraldehyde 3-phosphate and fructose 6-phosphate). The nonoxidative reactions are reversible, which may regenerate ribulose 5-phosphate from glycolytic intermediates. The oxidative PPP is a critical source of cytosolic NADPH that maintains reduced glutathione levels. Moreover, NAPDH contributes to the generation of cytosolic ROS through activation of NADPH oxidase and nitric oxide synthase. Thus, the PPP may play a dual role in the regulation of redox balance.

**PPP in the Hypertrophic Heart**

The role of the PPP in maintenance of cytosolic redox homeostasis has been reported from studies on glucose 6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the PPP. In response to cellular oxidative stress, G6PD activity is rapidly increased with corresponding translocation from the cytosol to the cell-surface membrane. At both in vitro and in vivo levels, G6PD shows a cardioprotective effect against free radical injury whereas depletion of G6PD causes adversity on cardiac contraction. In addition, G6PD-deficient mice display progressive pathological structural modeling and develop moderate hypertrophy at 9 months of age. Cardiac oxidative stress in these animals is augmented in response to MI or pressure overload. Glucose phosphorylation by hexokinase is the first step to initiate glucose utilization. Overexpression of hexokinase 2 shows an antihypertrophic effect in both phenylephrine-triggered hypertrophic cardiomyocytes and isoproterenol-induced cardiac hypertrophy in mice. Importantly, the beneficial effect of hexokinase 2 is associated with an elevated G6PD activity, leading to enhanced glucose utilization through the PPP and attenuated ROS accumulation. Taken together, increase in G6PD under various pathological conditions may serve as a defensive mechanism to protect cardiac myocytes against injury.

**PPP in the Ischemic and Failing Heart**

A detrimental effect of the oxidative PPP has been found in cardiac I/R. During acute I/R, the oxidative PPP-derived NAPDH is mostly metabolized by NAPDH oxidase and nitric oxide synthase. Inhibition of the oxidative PPP as well as NAPDH oxidase/nitric oxide synthase is cardioprotective against I/R-induced creatinine kinase release (an index of cardiac injury). Furthermore, an increase in G6PD expression and activity has been observed in both human and canine heart failure. Importantly, the PPP-derived NAPDH is also elevated and fuels superoxide production in failing hearts. Collectively, these observations strongly suggest that the increased availability of NAPDH, presumably through the oxidative PPP in failing hearts, may have a more-dominant effect on stimulating superoxide generation compared with its antioxidant role. Under the condition of severe heart failure, the glycolytic pathway is depressed. It is possible that a larger fraction of glucose entering cardiomyocytes triggers upregulation of the PPP. Interestingly, elevation of blood glucose after meals rapidly boosts the generation of ROS in failing hearts, but does not have an effect in normal hearts. This repeated physiological effect likely adds more oxidative stress to the failing heart. Indeed, inhibition of the oxidative PPP during acute hyperglycemia enhances cardiac glucose oxidation, oxygen consumption, and cardiac work and prevents oxidative stress in failing hearts. This inhibition may, however, be partial given that complete inhibition of oxidative PPP may cause an adverse effect, as observed in isolated adult cardiomyocytes. The partial inhibition is sufficient to maintain a proper balance of reduced glutathione for the antioxidant system while blunting the harmful, excessive level of NAPDH. It is, however, not clear whether...
sustained suppression of the oxidative PPP at the early stage of heart failure development would mitigate oxidative stress and dampen disease progression. It seems that in the onset of cardiac remodeling, the PPP acts as an adaptive response to accommodate cardiac stress by maintaining redox homeostasis.\textsuperscript{32} However, under persistent stress, the PPP may contribute to the pathogenesis of heart failure. The intracellular pathways mediating PPP actions remain to be fully characterized.

The important role of the PPP in maintaining proper intracellular redox states has also been revealed in cardiac progenitor cells (CPCs).\textsuperscript{114} The activities of key enzymes of the PPP (G6PD and transketolase) are reduced in CPCs of diabetic mice, leading to accumulation of glucose metabolic intermediates and execution of apoptosis. Importantly, upregulation of the PPP by benfotiamine treatment in diabetic mice restores G6PD and transketolase activities, decreases ROS and advance glycation end product accumulation, and prevents CPCs from cell demise. Consequently, development of cardiomyopathy and postischemic heart failure in diabetic mice is attenuated.\textsuperscript{114} The beneficial effect of the PPP in progression of heart failure has also been shown in Dahl salt-sensitive rats.\textsuperscript{115} Indeed, dichloroacetate treatment induces the PPP, which is involved in prevention of left ventricular hypertrophy and heart failure.

At the mechanistic level, decrease of the PPP in CPCs may be attributed to upregulation of glycolysis and glycerolipid biosynthesis.\textsuperscript{116} Salabei et al show that 6-phosphofructo-2-kinase/fructose 2,6-P\textsubscript{2} bisphosphatase 3, an isoform of PFK2, is significantly elevated in diabetic CPCs, which may promote usage of 3-carbon intermediates of glycolysis for glycerolipid production and consequently suppress glucose utilized for the PPP. This metabolic imbalance may lead to impairments in mitochondrial function and CPC proliferation. In agreement, the metabolite profiles of ex vivo rodent hearts perfused with glucose\textsuperscript{117} or PFK2 mutant-expressing cardiomyocytes\textsuperscript{118} show that PFK coordinately regulates glycolysis and other ancillary glucose metabolic pathways, including the PPP, the HBP, glycerolipid biosynthesis, and the polyclonal pathway. Activation of PFK causes a disproportionate distribution of glucose flux by directly limiting intermediates of glycolysis for ancillary glucose metabolic pathways and indirectly regulating the catabolic activity of mitochondria.\textsuperscript{118}

Along these lines, decrease in the PPP may also limit proliferation of fetal cardiomyocytes under diabetic conditions. Ribulose 5-phosphate is an important intermediate of the PPP pathway,\textsuperscript{119} which can be used for glucose production, glycolysis, pyrimidine nucleotide synthesis, purine nucleotide synthesis, and ATP generation. Recently, it has been shown that cardiomyocyte maturation is induced by nucleotide deprivation, not by cell-cycle blockage.\textsuperscript{120} Importantly, the role of nucleotide biosynthesis by the PPP is indicated as a primary determinant of the promitotic effect of glucose. These findings may provide certain mechanistic explanations for congenital heart disease in gestational diabetes mellitus, in which the high blood glucose level may suppress fetal cardiomyocytes proliferation. Therefore, targeting the PPP to control the proliferation of CPCs and cardiomyocytes may represent a promising approach for cardiac regeneration and treatment of diabetes mellitus–related cardiac disease.

Hexosamine Biosynthetic Pathway

At baseline, 2% to 5% of glucose is metabolized by the HBP, which has been found in adipocytes and skeletal muscle.\textsuperscript{121–123} This contribution can be significantly larger under stress conditions.\textsuperscript{124} The HBP is regulated by both nutrient inputs (glucose and glucosamine) and the rate-limiting enzyme, glutamine:fructose 6-phosphate amidotransferase (GFAT; Figure 5). GFAT converts fructose 6-phosphate to glucosamine 6-phosphate and eventually generates the final product, uridine diphosphate N-acetylg glucosamine (UDP-GlcNAc). UDP-GlcNAc serves as a substrate for the synthesis of proteoglycan, hyaluronan, glycolipid, glycosylphosphatidylino- nositol anchor, and N-glycan. Additionally, UDP-GlcNAc is used for O-GlcNAcylation, a prominent posttranslational modification of O-linked β-N-acetylg glucosamine (O-GlcNAc).\textsuperscript{125–128} The 2 key enzymes of O-GlcNAcylation are O-GlcNAc transferase (OGT) and O-GlcNAcase, which add the GlcNAc moiety donated from UDP-GlcNAc to, and remove from, target proteins at the Ser/Thr amino acid residues, respectively. This dynamic process plays a critical role in sensing cellular stressors, cell-cycle alterations, and nutrient levels, which has been implicated in the pathophysiology of various heart diseases.\textsuperscript{129–131}

HBP and O-GlcNAcylation in the Hypertrophic Heart

Previous studies have shown that the HBP and O-GlcNAcylation are activated during cardiac hypertrophy development. Indeed, pressure overload induces mRNA expression of GFAT2 and OGT and increases cardiac UDP-GlcNAc levels.\textsuperscript{132,133} Correspondingly, O-GlcNAc posttranslational modification on cardiac proteins is augmented.\textsuperscript{133–136} Moreover, the increase in O-GlcNAcylation has been revealed in hearts of hypertensive rats and aortic stenosis patients.\textsuperscript{133} Similarly, cardiomyocytes treated with hypertrophic stimuli (ie, phenylephrine, angiotensin II) show increases in O-GlcNAc levels whereas HBP inhibition causes a decrease in O-GlcNAc levels and counteracts the prohypertrophic effect.\textsuperscript{135,137}
These findings suggest that O-GlcNAcylation plays an important role in pathological cardiac hypertrophy, and inhibition of O-GlcNAcylation blunts hypertrophy progression. However, long-term reduction of O-GlcNAc levels is detrimental and causes cardiomyopathy.34,36 Furthermore, diabetes mellitus is associated with cardiac hypertrophy and elevation of O-GlcNAcylation.137–140 The increase of O-GlcNAcylation is accompanied by impaired cardiac hypertrophy in db/db diabetic hearts along with augmentation of B-cell lymphoma 2 (Bcl-2)-induced cardiomyocyte death, thereby accelerating the progression to heart failure.137 In both high-glucose–treated cardiac myocytes and hypertrophic myocardium of streptozotocin-induced diabetic rats, O-GlcNAc levels, extracellular signal–regulated kinase 1 and 2 (ERK1/2) activity, but not p38 mitogen-activated protein kinase or c-Jun N-terminal kinase (JNK) activity, and cyclin D2 expression are upregulated.139 Accordingly, inhibition of O-GlcNAcylation blocks activation of ERK1/2, hypertrophic growth, and cyclin D2 expression.139 ERK1/2 promotes compensatory cardiac hypertrophy, whereas p38 and JNK are involved in development of cardiomyopathy.141 In this context, O-GlcNAcylation may contribute to an adaptive form of cardiac hypertrophic growth.

The role of O-GlcNAcylation in cardiac hypertrophy is complex and depends on the type of hypertrophic growth.33 It is well known that calcineurin-NFAT (nuclear factor of activated T cells) signaling governs cardiac hypertrophy in response to pressure overload.142 O-GlcNAc modification on NFAT is required for its translocation from the cytosol to the nucleus, where NFAT stimulates the transcription of various hypertrophic genes. In other words, O-GlcNAc may contribute to cardiac hypertrophy through NFAT activation.143 Consistently, inhibition of O-GlcNAcylation dampens NFAT-induced cardiac hypertrophic growth. More recently, the antihypertrophic action of AMP-activated protein kinase has been firmly associated with reduction of O-GlcNAcylation.144 Importantly, O-GlcNAcylation of troponin T is one of the downstream targets of AMP-activated protein kinase in cardiac hypertrophic growth.144 There are several additional O-GlcNAcylated proteins from cardiac myofilaments, including cardiac myosin heavy chain, α-sarcomeric actin, myosin light chain 1 and 2, and troponin I.145 These key contractile proteins are O-GlcNAcylated at phosphorylated or nonphosphorylated sites. For example, myosin light chain 1 is O-GlcNAcylated at Thr 93/Thr 164, which are different from phosphorylation sites at Thr 69 and Ser 200.145,146 However, the O-GlcNAc residues in cardiac troponin I and myosin light chain 2 lie on the phosphorylation sites Ser 150 and Ser 15, respectively.145 At the functional level, O-GlcNAcylation of key contractile proteins may inhibit protein-protein interactions, resulting in reduction of calcium sensitivity, and thereby modulating contractile function.147

Figure 5. The hexosamine biosynthetic pathway (HBP) in the heart. The rate-limiting enzyme of the HBP, GFAT, converts fructose 6-P and glutamine to glucosamine 6-phosphate, which is used to generate the final product, UDP-GlcNAc. UDP-GlcNAc is a substrate for various biosynthetic pathways, including glycogen synthesis, glycerolipid production, etc. UDP-GlcNAc is also used for a prominent posttranslational protein modification on Ser/Thr sites by O-GlcNAc transferase (OGT), which is counteracted by O-GlcNAcase (OGA) to catalyze the removal of O-GlcNAc. GFAT indicates glutamine:fructose 6-phosphate amidotransferase; GLUT, glucose transporter; HK, hexokinase; UDP-GlcNAc, uridine diphosphate N-acetylglucosamine.
there is no change in OGT. Collectively, these findings highlight the role of O-GlcNAcylation in physiological cardiac hypertrophic growth.

**HBP and O-GlcNAcylation in the Ischemic and Failing Heart**

In response to various cellular stresses, the HBP and O-GlcNAcylation increase rapidly. Previous studies have shown that elevated O-GlcNAcylation confers strong cardioprotection in I/R. This is partly explained by increasing O-GlcNAcylated voltage-dependent anion channels and reducing sensitivity to mitochondrial permeability transition pore opening, thereby increasing mitochondrial tolerance to oxidative stress. In addition, induction of the HBP and O-GlcNAcylation by glucosamine promotes mitochondrial Bcl-2 translocation, which is associated with restoration of mitochondrial membrane potential and cardioprotection. Moreover, protection of increased O-GlcNAcylation has been proposed to attribute to depletion of the calcium-induced stress response. Recently, elevated O-GlcNAcylation and OGT expression along with reduction of OGA have been reported in infarction-induced heart failure in mice. Cardiomyocyte-specific deletion of OGT causes significant reduction in O-GlcNAcylation, which provokes heart failure after MI and impairs cardiac compensatory potential during heart failure development. Together, mounting evidence suggests that acute increase of O-GlcNAcylation is beneficial in the heart against various stressors.

As a metabolic and stress sensor, O-GlcNAcylation is altered in several chronic disease conditions, including heart disease. Induction of O-GlcNAcylation has been observed in hypertensive hearts, diabetic hearts, chronically hypertrophied hearts, and failing hearts. Studies have shown that this increase may contribute to contractile and mitochondrial dysfunction. Consistently, suppression of O-GlcNAcylation by overexpression of O-GlcNCase normalizes cardiac O-GlcNAcylation levels and improves calcium handling and cardiac contractility in the diabetic heart. Thus, it is speculated that the acute increase in O-GlcNAcylation is an adaptive response to protect the heart from injury, whereas prolonged, persistent activation is maladaptive and contributes to cardiac dysfunction.

Emerging evidence has shed light on the upstream regulators of the HBP. We have shown that GFAT1 is a direct target of X-box binding protein 1 (XBP1s), a key transcription factor of the unfolded protein response (UPR). Consistently, overexpression of XBP1s in cardiomyocytes promotes HBP activity, resulting in elevation of UDP-GlcNAc levels and O-GlcNAcylation. Notably, I/R activates XBP1s, which couples the UPR to the HBP to protect the heart from reperfusion injury. More recently, another UPR effector, activating transcription factor 4 (ATF4), has been demonstrated as a direct regulator of GFAT1 expression. Depivation of amino acids or glucose activates the general control non-derepressible 2/eukaryotic initiation factor 2 alpha/ATF4 pathway and leads to increases in GFAT1 and O-GlcNAcylation. Taken together, the HBP and cellular O-GlcNAcylation may serve as a buffering mechanism for the UPR to accommodate fluctuations in the cell in response to intracellular cues.

**Other Glucose Metabolic Pathways**

**Glycerolipid Synthetic Pathway**

Fructose 1,6-bisphosphate, an intermediate of glycolysis, can be converted to glyceraldehyde 3-phosphate and dihydroxyacetone phosphate. Dihydroxyacetone phosphate may then be reduced to glycerol 3-phosphate (glycerol 3-P) by glycerol 3-P dehydrogenase. Glycerol 3-P is derived from not only glucose through glycolysis, but also glycerol through the action of glycerol kinase, which serves as a substrate for acylation by glycerol 3-P acyltransferase, the first step of the glycerolipid synthetic pathway (GLP).

Although little is known about the role of the GLP in cardiomyopathy, the activities of glycerol 3-P dehydrogenase and glycerol 3-P acyltransferase, 2 crucial enzymes of the GLP, are elevated in hypertrophied hearts. Studies show that the GLP is, at least in part, associated with regulation of glycolysis by hypoxia-inducible factor 1 alpha (HIF-1α) and PFK. Emerging evidence indicates that HIF1α and peroxisome proliferator-activated receptor γ are elevated in pathological cardiac hypertrophy. Interestingly, induction of peroxisome proliferator-activated receptor γ expression by hypertrophy is HIF1α dependent, which subsequently induces glycerol 3-P acyltransferase. Therefore, hypertrophy-activated HIF1α triggers the synthesis of lipids by coregulation of glycolysis and GLP. At the functional level, HIF1α-mediated cardiac lipid accumulation leads to cell death through the HIF1α/peroxisome proliferator-activated receptor γ/octamer 1/growth arrest and DNA-damage-inducible α axis. Suppression of HIF1α therefore protects the heart from hypertrophy-induced cardiac dysfunction. This cardioprotection may be attributed to, at least partly, the increases of cAMP response element-binding protein activity and sarco/ER Ca2+-ATPase 2A expression. Additionally, activation of PFK in diabetic CPCs induces glycolysis and promotes the conversion of the 3-carbon intermediates of glycolysis to GLP. As a consequence, the GLP may initiate an adipogenic program in CPCs and contribute to lipid accumulation. In cardiomyocytes, low glycolytic activity may reduce glycerophospholipid synthesis at the glycerol 3-P dehydrogenase 1–committed step.
In contrast, high glycolytic activity could promote phosphatidylethanolamine synthesis while attenuating glucose-derived carbon incorporation into the FA chains of phosphatidylcholine and triacylglycerols.118 Taken together, these findings suggest that there is a concerted regulation of glycolysis and GLP in response to stress-induced pathological hypertrophy. Further work is needed to dissect the direct link of GLP with pathological cardiac remodeling.

Serine Biosynthetic Pathway
Serine biosynthesis is another ancillary glucose metabolic pathway to use glyceraldehyde 3-P to generate serine in 3 steps by phosphoglycerate dehydrogenase, phosphoserine aminotransferase 1, and phosphoserine phosphatase. Serine can be used to synthesize amino acids glycine and cysteine, which are biosynthetic precursors of glutathione, purine, and porphyrin. Serine may also constitute components of sphingolipids and phospholipids. In addition, serine provides the 1-carbon units to the 1-carbon metabolism pathway for purine, thymidine, methionine, and 5-adenosylmethionine synthesis.168 Because of the requirement of serine in the synthesis of various important molecules, it is proposed as a central metabolic regulator of cell function, growth, and survival.169,170 There are extensive studies on the role of serine biosynthesis in cancer168,171,172 whereas the importance in cardiac disease is poorly understood. Recently, activation of serine and the 1-carbon metabolism pathway induced by CnAP1, a calcineurin isoform, shows a protective effect in the heart under pressure overload.173 Induction of this pathway leads to increased ATP synthesis and reduced glutathione levels, improved cardiac contraction, and cardioprotection against oxidative injury. Further work is warranted to delineate the role of serine biosynthesis in cardiac physiology and pathophysiology.

Glycogen Metabolic Pathways
Glucose can be converted to glycogen, a multibranch polymer of glucose, for storage through the glycogen synthesis pathway. Cardiac glycogen serves as a significant source of glucose to support high energy demand not only in the normal heart, but also in the hypertrophied heart during normal aerobic perfusion174,175 or under low-flow ischemia.176,177 In the hypertrophied heart, glycolysis using glycogen-derived glucose is not altered compared with that in the normal heart whereas glycolysis with exogenous glucose is increased.175 Also, myocardial glycogen turnover occurs in both normal and hypertrophied hearts. During mild/moderate low-flow ischemia, rates of glycolysis as well as glucose oxidation are not different in the hypertrophied heart compared with those in the normal heart.176 The contribution of glycogen metabolism in the hypertrophied heart during normal aerobic flow or mild/moderate low-flow ischemia is similar to those in the normal heart. However, during severe low-flow ischemia, rates of glycolysis from both exogenous glucose and glycogen are augmented in the hypertrophied heart, along with the increase in glycogen turnover.

In ischemic preconditioning, reduced glycogenolysis and cardiac glycogen content may decrease glucose availability for glycolysis, lower acid production, and protect the heart from ischemic injury.178 In I/R, elevation in glycogen synthesis lowers the source of glucose for glycolysis, decreases acid generation, and prevents Ca2+ overload.179 In rats under fasting conditions, cardiac glycogen content is elevated, which protects the heart from ischemic damage. The increased glycogen utilization may serve as a critical source of ATP to maintain calcium homeostasis. On the other hand, fed rats similarly show elevation in cardiac glycogen content. However, the increase of circulating insulin limits glycogen utilization, which leads to an increase in lactate production and more-pronounced cardiac injury by ischemia.180 Taken together, understanding of the fundamental bases for glycogen homeostasis in cardiac pathophysiology is essential to harness the knowledge for therapeutic gain.

Pharmacological Agents to Modulate Metabolic Remodeling
There are a number of potential metabolic targets for treatment of heart diseases. The central goals of metabolic therapies are maintenance of flexibility in substrate use and the capacity of cardiac oxidative metabolism, which may, in turn, promote myocardial energy efficiency and improve cardiac function.181 FAO is a major contributor to energy production in the normal heart; however, FAO is less energy efficient than glucose oxidation because of its higher oxygen consumption. Therefore, optimizing cardiac energy metabolism by inhibiting FAO and inducing glucose oxidation may be a potential approach to treat heart failure.45,182

Inhibiting FA Uptake
Carnitine palmitoyltransferase 1 (CPT1) is a key enzyme for FA uptake into mitochondria. Direct modulation of FAO using carnitine palmitoyltransferase 1 inhibitors (eg, etomoxir and perhexiline) shows beneficial effects in treatment of heart failure. Etomoxir inhibits carnitine palmitoyltransferase 1 and suppresses FAO, along with augmented glucose oxidation, resulting in cardioprotection from ischemia.183 Treatment of etomoxir also improves myocardial performance of hypertrophied hearts following pressure overload184 and slows the progression from compensatory to decompensated cardiac
hypertrophy, in part, by inducing sarcoplasmic reticulum Ca\(^{2+}\) transport.\(^{185}\) Both etomoxir and perhexiline show beneficial effects on the improvement of left ventricular ejection fraction of patients with chronic heart failure.\(^{186,187}\) However, use of these agents for heart failure is limited (perhexiline) or even terminated (etomoxir) because of hepatotoxic side effects.

### Suppressing FA \(\beta\)-oxidation

Trimetazidine suppresses the rate of FAO by inhibiting 3 ketotacyl-CoA thiolase, the last enzyme in FAO, concomitant with increased glucose oxidation. Clinically, trimetazidine is used as an antianginal agent in the treatment for stable angina. It improves left ventricular ejection fraction in patients with either ischemic cardiomyopathy\(^{188}\) or idiopathic dilated cardiomyopathy.\(^{189}\) Especially, idiopathic dilated cardiomyopathy treatment with trimetazidine shows reduced FAO as well as increased insulin sensitivity. In addition, the improvement of ejection fraction by trimetazidine is more dramatic when used together with \(\beta\)-blockers, suggesting an additive effect of trimetazidine and \(\beta\)-adrenoceptor antagonism.\(^{189}\)

### Reducing Circulating FA

Glucose-insulin-potassium (GIK) increases glycolysis, reduces levels of circulating free FA, and hence decreases FAO. GIK had beneficial effects in patients with MI, shown by reduction of infarct size and mortality.\(^{190-194}\) However, effects of GIK are not always consistent. Some clinical studies have reported that GIK did not improve survival and decrease cardiac events in patients with acute MI.\(^{195,196}\) Clinical use of GIK remains to be fully validated.

### Increasing Glucose Oxidation

Activation of glucose oxidation is an effective way to provide a more energy-efficient substrate, which may show beneficial effects on improving cardiac function. Dichloroacetate (DCA) enhances glucose oxidation by activating the pyruvate dehydrogenase complex, which is associated with improvement of coupling between glycolysis and glucose oxidation in the heart after ischemia\(^{197}\) or pressure overload.\(^{198}\) Likewise, DCA promotes myocardial efficiency in patients with coronary artery disease.\(^{199}\) The beneficial effects of DCA in high-salt-diet–induced congestive heart failure in Dahl salt-sensitive rats are associated with increases in glucose uptake, cardiac energy reserve, and the PPP and the decrease in oxidative stress.\(^{115}\) However, DCA does not show its protective effects in patients with congestive heart failure.\(^{200}\) In diabetic rat hearts, although DCA treatment during reperfusion significantly augments glucose oxidation, DCA has no effect on functional recovery from ischemic injury. Glucose oxidation may not be a key factor in governing the ability of diabetic rat hearts to recover from I/R.\(^{201}\)

### Conclusions and Future Perspectives

Numerous studies have firmly established that heart failure is associated with profound metabolic remodeling. Multiple layers of crosstalk exist among individual glucose metabolic pathways to regulate substrate availability and ATP production. The increase in glucose metabolism in onset of heart disease is associated with an adaptive mechanism to protect the heart from injury. Chronic activation, however, may lead to decompensation and heart failure progression. Metabolic remodeling plays an essential role in regulating not only nutrient utilization, but also ionic and redox homeostasis, UPR, and autophagy, thereby affecting cardiac contractile function. A better and more-thorough understanding of the mechanisms of action and regulation may pave a new way for therapeutic discoveries to tackle heart failure.

### Sources of Funding

This work was supported by grants from American Heart Association (14SDG18440002, 17IRG33460191), American Diabetes Association (1-17-IBS-120), and NIH (HL137723) (to Wang).

### Disclosures

None.

### References

1. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiue SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Issaci CR, Jimenez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolini ME, Nasir K, O’Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchie MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. Circulation. 2018;137:e67–e492.

2. Braunwald E. Heart failure. Circulation. 1997;337:1360–1369.

3. Drazner MH. The progression of hypertensive heart disease. Circulation. 2011;123:327–334.

4. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cells Biol. 2006;7:589–600.

5. Ashrafi L, Hennaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation. 2007;116:434–448.

6. Doenst T, Nguyen TD, Abel ED. Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res. 2013;113:709–724.

7. Kundu BK, Zhong M, Sen S, Davugostto G, Keller SR, Taegmeyer H. Remodeling of glucose metabolism precedes pressure overload-induced left ventricular hypertrophy: a review of a hypothesis. Cardiology. 2015;130:211–220.
Glucose Metabolism in Heart Disease
Tran and Wang

8. Ritterhoff J, Tian R. Metabolism in cardiomyopathy: every substrate matters. *Cardiovasc Res*. 2015;107:411–421.

9. Wende AR, Brahma MK, McGinnis GR, Young ME. Metabolic origins of heart failure. *JACC Basic Transl Sci*. 2017;2:297–310.

10. Gibb AA, Hill BG. Metabolic coordination of physiological and pathological cardiac remodeling. *Circ Res*. 2018;123:107–128.

11. Abel ED. Glucose transport in the heart. *Front Biosci*. 2004;9:201–215.

12. Abel ED, Kaubach HC, Tian, R, Hopkins JC, Duffy, J, Doetschman T, Minnemann T, Boers ME, Hadro E, Oberste-Berghaus C, Quist W, Lowell BB, Ingwall JS, Kahn BB. Cardiac hypertrophy with preserved contractile function—selective deletion of GLUT4 from the heart. *J Clin Invest*. 1999;104:1703–1714.

13. Tian R, Abel ED. Responses of GLUT4-deficient hearts to ischemia underscore the importance of glycolysis. *Circulation*. 2001;103:2961–2966.

14. Liao R, Jain M, Cui L, DAngostino J, Aiello F, Luptak I, Ngoy S, Mortensen RM, Tian R. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. *Circulation*. 2002;106:2125–2131.

15. Pereira RO, Wende AR, Olsen C, Soto J, Rawlings T, Zhu Y, Anderson SM, Abel ED. Inducible overexpression of GLUT1 prevents mitochondrial dysfunction and attenuates structural remodeling in pressure overload but does not prevent left ventricular dysfunction. *J Am Heart Assoc*. 2013;2:e000301. DOI: 10.1161/JAHA.113.000301.

16. Pereira RO, Wende AR, Olsen C, Soto J, Rawlings T, Zhu Y, Riehle C, Abel ED. GLUT1 deficiency in cardiomyocytes does not accelerate the transition from compensated hypertrophy to heart failure. *J Mol Cell Cardiol*. 2014;72:95–103.

17. Chanda D, Luiken JJ, Glotz JF. Signaling pathways involved in cardiac energy oxidation in cardiac hypertrophy. *FASEB J*. 2007;21:3069–3083.

18. Li XB, Gu JD, Zhou QH. Review of aerobic glycolysis and its key enzymes – new targets for lung cancer therapy. *Thorac Cancer*. 2015;6:17–24.

19. Kashiwai Y, Sato K, Tsuichina N, Thomas S, Fell DA, Veel RL, Passonneau JV. Control of glucose utilization in working perfused rat heart. *J Biol Chem*. 1994;269:25502–25514.

20. Hue L, Rider MH. Role of fructose 2,6-bisphosphate in the control of glycolysis in mammalian tissues. *Biochem J*. 1987;245:313–324.

21. Dhar-Chowdhury P, Malester B, Rajacic P, Coetzee WA. The regulation of ion channels and transporters by glycolytically derived ATP. *Cell Mol Life Sci*. 2007;64:3069–3083.

22. Leong HS, Brownswy RA, Wulpe JE, Allard MF. Glycolysis and pyruvate oxidation in cardiac hypertrophy—why so unbalanced? *Comp Biochem Physiol A Mol Integr Physiol*. 2003;135:499–513.

23. Nascimben L, Ingwall JS, Lorell BH, Pinz R, Schultz V, Tornehim K, Tian R. Mechanisms for increased glycolysis in the hypertrophied rat heart. *Cardiovasc Res*. 2004;62:467–477.

24. Donthi RV, Ye G, Wu C, McClain DA, Lange AJ, Epstein PN. Cardiac expression of kinase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase inhibits glycolysis, promotes hypertrophy, impairs myocyte function, and reduces insulin sensitivity. *J Biol Chem*. 2004;279:48085–48090.

25. Wang J, Xu J, Wang Q, Brainard RE, Watson LJ, Jones SP, Epstein PN. Reduced cardiac fructose 2,6-bisphosphate increases hypertrophy and decreases glycolysis following aortic constriction. *PLoS One*. 2013;8:e5951.

26. Gibb AA, Epstein PN, Uchida S, Zheng Y, McNally LA, Obal D, Katragadda K, Trainor P, Conklin DJ, Brittard KR, Tseng MT, Wang J, Jones SP, Bhatnagar A, Hill BG. Exercise-induced changes in glucose metabolism promote physiologic cardiac growth. *Circulation*. 2017;136:2144–2157.

27. Wang Q, Donthi RV, Wang J, Lange AJ, Watson LJ, Jones SP, Epstein PN. Cardiac phosphatase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase increases glycolysis, hypertrophy, and myocyte resistance to hypoxia. *Am J Physiol Heart Circ Physiol*. 2008;294:H2889–H2897.

28. Baba SP, Zhang D, Singh M, Dassanayaka S, Xie Z, Jagatheesan G, Zhao J, Schmidtke JW, Brittard KR, Merchant ML, Conklin DJ, Jones SP, Bhatnagar A. Deficiency of aldose reductase exacerbates early pressure overload-induced cardiac dysfunction and autopsy in mice. *J Mol Cell Cardiol*. 2018;118:183–192.

29. Son NH, Ananthakrishnan R, Yu S, Khan RS, Jiang H, Ji R, Akashi H, Li Q, O’Shea K, Homma S, Goldberg IJ, Ramasamy R. Cardiomyocyte aldose reductase causes heart failure and impairs recovery from ischemia. *PLoS One*. 2012;7:e46549.

30. Jain M, Brenner DA, Cui L, Lim CC, Wang B, Pimentel DR, Koh S, Sawyer DB, Leopold JA, Handy DE, Loscalzo J, Apstein CS, Liao R. Glucose-6-phosphate dehydrogenase modulates cytokotic redox status and contractile phenotype in adult cardiomyocytes. *Circ Res*. 2003;93:e9–e16.
Glucose Metabolism in Heart Disease

51. Fillmore N, Mori J, Lopaschuk GD. Mitochondrial fatty acid oxidation alterations in heart failure, ischemic heart disease and diabetic cardiomyopathy. Br J Pharmacol. 2014;171:2080–2090.

52. Paolillo G, Gambardella A, Galzerano D, D’Amore A, Rubino P, Verza M, Teasuro P, Vannicchi M, D’Onofrio F. Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism. 1994;43:174–179.

53. Taylor M, Wallhaus TR, Degrado TR, Russell DC, Stanko P, Nickles RJ, Stone CK. An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-2-thio-decanoic acid and [18F]FDG in patients with congestive heart failure. J Nucl Med. 2001;42:55–62.

54. Lommi J, Kupari M, Yi-Jarvinen H. Free fatty acids kinetics and oxidation in congestive heart failure. Am J Cardiol. 1998;81:45–50.

55. Diakos NA, Navankasattusas S, Abel ED, Rutter J, McCreadth L, Ferrin P, McKeil SH, Miller DV, Park SY, Richardson RS, Deberardinis R, Cox JE, Kfouri AG, Seelman CH, Stehlik J, Fang JC, Li DY, Drako SG. Evidence of glycolysis up-regulation and pyruvate myocardial oxidation mismatch during mechanical unloading of the failing human heart: implications for cardiac reloading and conditioning. JACC Basic Trans Sci. 2016;1:432–444.

56. Fillmore N, Levasseur JL, Fukushima A, Dyck JRB, Fillmore N, Levasseur JL, Fukushima A, Wagg CS, Wang W, Dyck JRB, Fillmore N, Levasseur JL, Fukushima A, Wagg CS, Wang W, Dyck JRB, Fillmore N, Levasseur JL, Fukushima A, Wagg CS, Wang W, Dyck JRB, Fillmore N, Levasseur JL, Fukushima A, Wagg CS, Wang W, Dyck JRB.

57. Heather LC, Cole MA, Lygate CA, Evans RD, Stuckey DJ, Murray AJ, Neubauer S. Free fatty acid kinetics and oxidation in congestive heart failure with preserved ejection fraction. Mol Cell Proteomics. 2004;3:167–175.

58. Li J, Kemp BA, Howell NL, Massey J, Minzuk K, Huang Q, Chordia MD, Roy RJ, Patrice JT, Davoguotto GE, Kramer CM, Epstein FH, Carey RM, Taegtmeyer H, Keller SR, Kundu BK. Metabolic changes in spontaneously hypertensive rat hearts precede acute cardiac dysfunction and left ventricular hypertrophy. J Am Heart Assoc. 2019;8:e010926. DOI: 10.1161/JAHA.118.010926.

59. Wang ZY, Hill JA. Protein quality control and metabolism: bidirectional control in the heart. Cell Metab. 2015;21:215–226.

60. Srivastava S, Chandra A, Ansari NH, Srivastava SK, Bhatnagar A. Identification of cardiac oxidoreductase(s) involved in the metabolism of the lipid peroxidation-derived aldehyde-4-hydroxynonenal. Biochem J. 1998;329:469–475.

61. Srivastava S, Chandrasekhar B, Bhatnagar A, Prabhu SD. Lipid peroxidation-derived aldehydes and oxidative stress in the failing heart: role of aldose reductase. Am J Physiol Heart Circ Physiol. 2002;283:H2612–H2619.

62. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, van den Enden M, Kilo C, Tilton RG. Hyperglycemic superoxide and diabetic complications. Diabetologia. 1993;49:801–813.

63. Dunlop M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int. 2000;58:S3–S12.

64. Vikramadityan RK, Hu Y, Noh HL, Liang CP, Hallam K, Tall AR, Ramasamy R, Goldberg IJ. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J Clin Invest. 2005;115:2434–2443.

65. Ramasamy R, Goldberg IJ. Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. Circ Res. 2010;106:1449–1455.

66. Vedantham S, Noh H, Ananthakrishnan R, Son N, Hallam K, Hallam K, Tall AR, Ramasamy R, Goldberg IJ, Ramasamy R. Human aldose reductase expression accelerates diabetic atherosclerosis in diabetic apolipoprotein E−/− mice. Arterioscler Thromb Vasc Biol. 2011;31:1905–1913.

67. Ramasamy R, Trueblood N, Schaefer S. Metabolic effects of aldose reductase inhibition during low-flow ischemia and reperfusion. Am J Physiol. 1998;275:H195–H203.

68. Hwang YC, Sato Y, Tsai YJ, Yen SC, Birk S, Zhang H, Oates PJ, Ramasamy R. Aldose reductase activation is a key component of myocardial response to ischemia. J Pharmacol Sci. 2006;102:37–46.

69. Ita Y, Matsuoka K, Nishimura T, Persson C, Yabe-Nishimura C. Aldose reductase inhibitors improve myocardial reperfusion injury in mice by a dual mechanism. J Pharmacol Sci. 2006;102:37–46.

70. Kasimov KM, Srivastava S, Hoekstra JW, Awe SO, Tang RL, Cai J, Bhatnagar A. Redox activation of aldose reductase in the ischemic heart. J Biol Chem. 2006;281:15110–15120.

71. Ananthakrishnan R, Kaneko M, Hwang YC, Quadri N, Gomez T, Li Q, Rosario R, Lu Y, Ravindranath T, Drosatos K, Huggins LA, Schmidt AM, Goldberg IJ, Ramasamy R. Human aldose reductase expression accelerates diabetic complications in an experimental model. Circ Res. 2010;106:1449–1455.

72. Tong Y, Li D, Yang Q, Hu Y, Li Q, Zhang W, Cao J, Wang H, Oates PJ. Aldose reductase inhibition during acute hyperglycemia due to impaired serum of SERTA by polyol pathway-mediated oxidative stress. Am J Physiol. 2010;299:C643–C653.

73. Ananthakrishnan R, Li Q, Gomes T, Schmidt AM, Ramasamy R. Aldose reductase pathway contributes to vulnerability of aging myocardium to ischemic injury. Exp Gerontol. 2011;46:762–767.

74. Ramasamy R, Oates PJ, Schaefer S. Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes. 1997;46:292–300.

75. Tang WH, Wu S, Wong TM, Chung SK, Chung SS. Polyol pathway mediates iron-induced oxidative injury in ischemic-reperfused rat heart. Free Radic Biol Med. 2008;45:602–610.

76. Trueblood N, Ramasamy R. Aldose reductase inhibition improves altered glucose metabolism of isolated diabetic rat hearts. Am J Physiol. 1998;275:H75–H83.

77. Hwang YC, Birk S, Ellery CA, Oates PJ, Ramasamy R. Sorbitol dehydrogenase: a novel target for adjunctive protection of ischemic myocardium. FASEB J. 2002;17:2331–2333.

78. Ramasamy R, Liu H, Oates PJ, Schaefer S. Attenuation of ischemia induced increases in sodium and calcium by the aldose reductase inhibitor zopolrestat. Cardiovasc Res. 1999;42:130–139.
Glucose Metabolism in Heart Disease

138. Hu Y, Suarez J, Fricovsky E, Wang H, Scott BT, Traeger SA, Han W, Hu Y, Ozturk VM, Dillmann WH. Increased enzymatic O-GlcNAcylation of mitochondrial proteins impairs mitochondrial function in cardiac myocytes exposed to high glucose. *J Biol Chem*. 2009;284:547–555.

139. Ding F, Yu L, Wang M, Xu S, Xia Q, Fu G. O-GlcNAcylation involvement in high glucose-induced cardiac hypertrophy via ERK1/2 and cyclin D2. *Amino Acids*. 2013;45:339–349.

140. Laczzy B, Hill BG, Wang K, Paterson AJ, White CR, Xing D, Chen YF, Darley-Usmar V, Oparil S, Chatham JC. Protein O-GlcNAcylaton: a new signalling paradigm for the cardiovascular system. *Am J Physiol Heart Circ Physiol*. 2009;296:H122–H128.

141. Bueno OF, De Windt LJ, Klevitsky R, Hewett DJ, Xing D, Chen YF, Darley-Usmar VM, Ball LE, Chatham JC. Protein O-linked beta-N-acetylglucosaminyltransferase: a novel effector of cardiomyocyte metabolism and function. *J Mol Cell Cardiol*. 2012;52:538–549.

142. Barnerjee PS, Lagerof D, Hart GW.Roles of O-GlcNAc in chronic diseases of aging. *Mol Aspects Med*. 2016;51:1–15.

143. Maitieux F, Gelinas R, Beaulage C, Hormann S, Bertrand L. O-GlcNAcylaton, enzyme or ally during cardiac hypertrophy development? *Biochim Biophys Acta*. 2016;1862:2232–2243.

144. Lima RV, Rigsby CS, Hardy DM, Webb RC, Tostes RC. O-GlcNAcylaton: a novel post-translational mechanism to alter vascular cellular signaling in health and disease: focus on hypertension. *J Am Soc Hypertens*. 2009;3:374–387.

145. Clark RJ, McDonough PM, Swanson E, Trost SJ, Suzuki M, Fukuda M, Dillmann WH. Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylaton. *J Biol Chem*. 2003;278:44230–44237.

146. Fulp N, Mason MM, Dutta K, Wang P, Davidoff AJ, Marchase RB, Chatham JC. O-linked GlcNAc incorporation in normal and diabetic cardiomyocytes. *Am J Physiol Heart Circ Physiol*. 2007;292:C1370–C1378.

147. Hu Y, Belke D, Suarez J, Swanson E, Clark R, Hoshijima M, Dillmann WH. Adenosine-mediated overexpression of O-GlcNAcase improves contractile function in the diabetic heart. *Circ Res*. 2005;96:1006–1013.

148. Chevaroux C, Sarcinelli C, Barbet V, Belfeki S, Barthelaix A, Ferraro-Peyret C, Lebecque S, Renno T, Bruhat A, Fafournoux P, Manie SN. Nutrient shortage triggers the hexosamine biosynthetic pathway via the GCN2-ATF4 signalling pathway. *Sci Rep*. 2016;6:27278.

149. Mattaini KR, Sullivan MR, Vander Heiden MG. The importance of serine metabolism in cancer. *J Cell Biol*. 2016;214:249–257.

150. Ducker GS, Rabinowitz JD. One-carbon metabolism in health and disease. *Circulation*. 2017;125:27–42.

151. Gao X, Lee K, Reid MA, Sandersson SM, Liu J, Liu J, Locasale JW. Serine availability influences mitochondrial dynamics and function through lipid metabolism. *Cell Rep*. 2018;22:3507–3520.

152. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, Sethumadhavan S, Woo HK, Jang HG, Hja AK, Chen WW, Barrett FG, Stranks NY, Tsun ZY, Cowley GS, Barretina J, Kalaany NY, Hsu PP, Ottina K, Chan AM, Yuan B, Garraway LA, Root DE, Mino-Kenudson M, Brachtel EF, Driggers EM, Sabatini DM. Functional genomics reveal that the serine biosynthesis pathway is essential in breast cancer. *Nature*. 2011;476:346–350.

153. Yang M, Voussen KH. Serine and one-carbon metabolism in cancer. *Nat Rev Cancer*. 2016;16:650–662.

154. Padron-Barthe L, Vilalta-Otero M, Gomez-Salineiro JM, Acin-Perez R, Cogliati S, Lopez-Olana M, Vázquez-Sanchez P, Bonzon-Kulichenko E, Vaquero J, Garcia-Pavia P, Rosenthal N, Enriquez JA, Lara-Pezei E. Activation of serine one-carbon metabolism by calcium-calcineurin inhibition reduces myocardial hypertrophy and improves ventricular function. *J Am Coll Cardiol*. 2018;71:654–667.

155. Henning SL, Wambolt RB, Schönekess BO, Lopashuk GD, Allard MF. Contribution of glycogen to aerobic myocardial glycerol utilization. *Circulation*. 1996;93:1549–1555.

156. Allard MF, Henning SL, Wambolt RB, Granleese SR, English DR, Lopashuk GD. Glycerol metabolism in the aerobic hypertrophied rat heart. *Circulation*. 1997;96:676–682.

157. Schönekess BO, Allard MF, Henning SL, Wambolt RB, Lopashuk GD. Contribution of glycerol and exogenous glucose to glucose metabolism during ischemia in the hypertrophied rat heart. *Circ Res*. 1997;81:540–549.

158. Wambolt RB, Henning SL, English DR, Dyachkova Y, Lopashuk GD, Allard MF. Glycerol utilization and glycogen turnover are accelerated in hypertrophied rat hearts during severe low-flow ischemia. *J Mol Cell Cardiol*. 1999;31:493–502.

159. McNulty PH, Darling A, Whiting JM. Glycerol depletion contributes to ischemic preconditioning in the rat heart in vivo. *Am J Physiol*. 1996;271:H2283–H2289.

160. Omar MA, Wang L, Clanagan AS. Cardioprotection by GSK-3 inhibition: role of enhanced glycerol synthesis and attenuation of calcium overload. *Cardiovasc Res*. 2010;86:478–486.

161. Schaefer S, Ramasamy R. Glycerol utilization and ischemic injury in the isolated rat heart. *Cardiovasc Res*. 1997;35:90–98.
Glucose Metabolism in Heart Disease  Tran and Wang

181. Karwi OG, Uddin GM, Ho KL, Lopaschuk GD. Loss of metabolic flexibility in the failing heart. Front Cardiovasc Med. 2018;5:68.

182. Lioniatti V, Stanley WC, Recchia FA. Modulating fatty acid oxidation in heart failure. Cardiovasc Res. 2011;90:202–209.

183. Lopaschuk GDWS, Olley PM, Davies NJ. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res. 1988;63:1036–1043.

184. Turcani M, Rupp H. Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation. 1997;96:3681–3686.

185. Rupp H, Vetter R. Sarcoplasmic reticulum function and carnitine palmitoyltransferase I inhibition during progression of heart failure. Br J Pharmacol. 2000;131:1748–1756.

186. Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in the failing heart. Circulation. 1996;93:758–759.

187. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Schmidt-Schweda S, Holubarsch C. Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation. 1997;96:3681–3686.

188. Fragasso G, Perseghin G, De Cobelli F, Esposito A, Pallosli A, Lattuada G, Scillo P, Caloni G, Del Maschio A, Margonato A. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J. 2006;27:942–948.

189. Tuunanen H, Engblom E, Naum A, Nagren K, Scheinin M, Hesse B, Juhani Airaksinen KE, Nuutila P, Izoz P, Ukkonen H, Opie LH, Knudt J. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation. 2008;118:1250–1258.

190. Sodi-Pallara D, Testell MR, Fishtedier BL, Bisteni A, Medrano GA, Friedland C, De Micheli A. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report. Am J Cardiol. 1962;9:166–181.

191. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction. Eur Heart J. 1996;17:1337–1344.

192. Diaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, Corvalan R, Isea JE, Romero G. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group. Circulation. 1998;98:2227–2234.

193. Jonasson AK, Aasum E, Riipersma RA, Mijas OD, Larsen TS. Glucose-insulin-potassium reduces infarct size when administered during reperfusion. Cardiovasc Drugs Ther. 2000;14:615–623.

194. van der Horst IC, Zijlstra F, van’t Hof AW, Doggen CJ, de Boer MJ, Suryapranata H, Hoornje JC, Dambrink JH, Gans ROB, Bilo HJ; Zwolle Infarct Study Group. Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2003;42:784–791.

195. Ceremuzynski L, Budaj A, Czepiel A, Burzykowski T, Achremczyk P, Smielak-Korombel W, Maciejewicz J, Dzubielska J, Nartowicz E, Kawa-Ka-Urbanek T, Piotrowski W, Hanzlik J, Ciesliński A, Kweckla-Jaszcz K, Gessek J, Wrbic K. Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: results of a randomized multicenter Pol-GIK trial. Cardiovasc Drugs Ther. 1999;13:191–200.

196. van der Horst IC, Timmer JR, Ottervanger JP, Bilo HJ, Gans RO, de Boer MJ, Zijlstra F; GIPS Investigators. Glucose-insulin-potassium and reperfusion in acute myocardial infarction: rationale and design of the Glucose-Insulin-Potassium Study-2 (GIPS-2). Am Heart J. 2005;149:585–591.

197. Liu B, Clanachan AS, Schulz R, Lopaschuk GD. Cardiac efficiency is improved after ischemia by altering both the source and fate of protons. Circ Res. 1996;79:940–948.

198. Lydell CP, Chan A, Wambolt RB, Sambandam N, Parsons H, Bondy GP, Rodrigues B, Popov KM, Harris RA, Brownsey RW, Allard MF. Pyruvate dehydrogenase and the regulation of glucose oxidation in hypertrophied rat hearts. Cardiovasc Res. 2002;53:841–851.

199. Wargovich TJ, MacDonald RG, Hill JA, Feldman RL, Stacpoole PW, Pepine CJ. Myocardial metabolic and hemodynamic effects of dichloroacetate in coronary artery disease. Am J Cardiol. 1988;61:65–70.

200. Lewis JF, DaCosta M, Wargovich TJ, Stacpoole PW. Effects of dichloroacetate in patients with congestive heart failure. Clin Cardiol. 1998;21:888–892.

201. Gamble J, Lopaschuk GD. Glycolysis and glucose oxidation during reperfusion of ischemic hearts from diabetic rats. Biochim Biophys Acta. 1994;1225:191–199.

Key Words: glucose metabolism • heart failure • ischemic heart disease • pathological cardiac remodeling